The efficacy of intravenous ceftriaxone, 2 g per day for 30 days, was evaluated in a case series of 18 consecutive patients who met strict criteria for Lyme encephalopathy. Months to years after classic manifestations of Lyme disease, the 18 patients presented with memory difficulty, minor depression, somnolence, or headache. Sixteen (89%) had abnormal memory scores; 16 (89%) had cerebrospinal fluid (CSF) abnormalities, and all 7 patients tested had frontotemporal perfusion defects on single photon emission computed tomographic (SPECT) imaging. Six months after treatment, memory scores in the 15 patients who completed the study according to protocol were significantly improved ( ). In the 10 patients who had P ! .01 follow-up CSF analyses, total protein levels were significantly lower ( ). In the 7 patients P ! .05 who had SPECT imaging, posttreatment perfusion was significantly better ( ). Twelve P ! .01 to 24 months after treatment, all 18 patients rated themselves as back to normal or improved. We conclude that Lyme encephalopathy can be treated successfully with ceftriaxone.
chain reaction (PCR) may detect B. burgdorferi DNA [8] , local production of antibody to B. burgdorferi [9] , or the less specific finding of elevated protein [3] , or the CSF may be normal [3] [4] [5] . CSF pleocytosis, a frequent finding in early Lyme neuroborreliosis, is rarely found in Lyme encephalopathy. In addition, brain magnetic resonance imaging (MRI), even with gadolinium enhancement, is usually normal, although nonspecific white matter lesions are seen in some patients [3] [4] [5] [6] .
There are only a few previous studies of Lyme encephalopathy. In an initial study, Halperin et al. [4] reported clinical features and neuropsychological test results in 17 patients with Lyme encephalopathy. The patients had significant improvement in the California Verbal Memeory Test (CVLT) and Wechsler memory scores after antibiotic treatment, but the diagnostic entrance criteria were not specified, the antibiotic regimen was not standardized, and the duration of follow-up was only 5-28 weeks. In a subsequent series of 65 patients with various neurological manifestations of Lyme disease, Halperin et al. reported 21 patients with symptoms of encephalopathy who had abnormalities on the bedside Mini-Mental Status Examination [6] . Almost all of the patients improved after treatment with intravenous (iv) ceftriaxone, but the parameters for measuring response were not spelled out.
Our initial report was a case series of 27 patients with chronic neuroborreliosis, 24 of whom had encephalopathy [3] . All but 1 of these patients had objective abnormalities on formal neuropsychological tests of memory or abnormal CSF analyses. As measured 6 months after treatment with iv ceftriaxone, 2 g once a day for 2 weeks, 17 patients (63%) improved, 6 (22%) had improvement but then relapsed, and 4 (15%) had no change in their condition. However, this was not a formal treatment study with uniform entrance criteria, outcome measures, and prolonged follow-up.
In 1985, Dattwyler et al. began a series of studies to test ceftriaxone in the treatment of late Lyme disease. In their initial study, 23 patients with Lyme arthritis, encephalopathy, or polyneuropathy, alone or in combination, were randomized to receive iv penicillin, 20 million U/d for 10 days, or iv ceftriaxone, 4 g per day for 14 days [10] . In the next phase of the study, 31 patients were randomized to receive ceftriaxone, 2 or 4 g per day for 2 weeks [10] . Altogether, 37 of the patients had symptoms of encephalopathy. Although most of the patients had gradual improvement after this therapy, 5 of 7 given penicillin versus only 3 of 30 who received one of the ceftriaxone regimens continued to have symptoms ( ). Finally, in an open-P ! .002 labeled, randomized multicenter study, patients with late manifestations of Lyme disease-primarily Lyme arthritis but, in some instances, chronic neuroborreliosis-were treated with iv or intramuscular ceftriaxone for 2 or 4 weeks [11] . Symptoms resolved in 76% of those treated for 2 weeks and in 70% of those who received 4 weeks of therapy (P not significant). Among patients with persistent symptoms, the most common ones were arthralgia, weakness, malaise, or fatigue. It was concluded that 2 g per day of iv ceftriaxone for 2 weeks was equivalent to higher doses and longer courses for the treatment of late Lyme disease. However, since the diagnosis of encephalopathy was based on clinical symptoms and serological results, and since end points for improvement were subjective, the objective treatment response of strictly defined Lyme encephalopathy to iv ceftriaxone of 2 or 4 weeks' duration still remains unclear.
In the present study, our goal was to evaluate the efficacy of iv ceftriaxone, 2 g once per day for 30 days, in patients who met strict criteria for Lyme encephalopathy, using 3 objective outcome measures in addition to subjective improvement in symptoms. Because documented Lyme encephalopathy is rare (we see only 2 or 3 such patients per year), the study design was an observational case series of a single antibiotic regimen. Treatment for 4 weeks was selected because previous series, including our own, suggested that relapse may sometimes occur with 2 weeks of therapy. Although some of the patients had been treated previously with antibiotics, none had received a 1-month course of iv ceftriaxone.
Methods
Entrance criteria. During a 7-year period, from January 1989 through December 1995, we enrolled 18 consecutive patients who met criteria for Lyme encephalopathy in a treatment study of iv ceftriaxone. The protocol was approved by the Human Investigations Committee at New England Medical Center. As in previous studies [3, 12, 13] , a patient with Lyme encephalopathy was characterized as having (1) previous classical manifestations of Lyme disease, (2) current neuropsychiatric symptoms, and (3) evidence of past or present B. burgdorferi infection in CSF, demonstrated by intrathecal antibody production or spirochetal DNA; or a positive IgG antibody response to B. burgdorferi, detected by ELISA and Western blotting, and verbal or visual memory impairment, as demonstrated by a score at least 2 SDs below the mean of normal control subjects. Patients were excluded if they had (1) a preexisting condition associated with cognitive impairment or (2) a history of alcohol or other drug abuse or (3) if, at any time, they had received a 1-month course of iv ceftriaxone for treatment of Lyme disease.
During the study period, 36 patients with previous classical manifestations of Lyme disease and current neuropsychiatric symptoms (see below) were seen at the Lyme Disease Clinic at the New England Medical Center. Of the 36 patients, 18 met the entrance criteria (the intention-to-treat group). Of the 18 patients who did not meet these criteria, 7 lacked objective abnormalities on neuropsychological tests or evidence of past or present B. burgdorferi infection in spinal fluid, 5 had a preexisting illness associated with cognitive impairment, 1 had a history of alcohol abuse, and 5 had already received treatment with у1 month of IV ceftriaxone.
Evaluation according to protocol. Patients were required to have pretreatment serological testing, lumbar puncture, neuropsychological testing, and brain MRI. The antibody response to B. burgdorferi in serum was determined by indirect ELISA and Western blotting [14] , and positive results were interpreted according to the CDC/ASTPHLD criteria [15] . Spinal fluid was tested for total cells and protein, and concomitant serum and CSF samples were tested for intrathecal IgM, IgG, and IgA antibody production to B. burgdorferi by antibody capture enzyme assay, as previously described [9] . A response in CSF that was 11 times that in serum was defined as local synthesis of specific antibody in CSF. B. burgdorferi DNA was detected in CSF by PCR by use of 2 different primer-probe sets that target different regions of the plasmid DNA encoding outer-surface protein A of the spirochete, as previously described [8] .
When the study was begun, only limited information was available regarding neurocognitive abnormalities of Lyme disease. Therefore, a comprehensive general survey of neurocognitive function was performed to provide measures of attention and concentration, psychomotor skills, visuospatial organization, word fluency, and immediate and delayed verbal and visual memory [3, 12] . These included the digit span and digit symbol subtests of the Wechsler Adult Intelligence Scale-Revised, the Trail-Making Test, the Hooper Visual Organization Test, the Rey-Osterrieth Complex Figure Test , the Controlled Word Association Test, and the CVLT. Symptoms of depression were assessed by the Beck Depression Inventory. In 1990, an analysis of neuropsychological test results showed that when deficits were present, they almost exclusively involved memory [3] . Therefore, in 1991, a decision was made to substitute the Selective Reminding Test (SRT) for the CVLT test of memory, since the SRT has a greater number of versions. Because verbal memory over the 7-year period of the study was measured using 2 different tests (4 received the CVLT and 11 received the SRT), a verbal learning score was computed by transforming the raw scores from each test into standard t scores based on agecorrected normative data [16, 17] . As in previous studies of Lyme [3, 14] and human immunodeficiency virus [18] a Values are n (%) unless otherwise indicated. scored 1 SD below the mean on both the verbal and the visual memory tests. Routine brain MRI, without gadolinium enhancement, was performed in all patients. After August 1992, it became possible to perform quantitative single photon emission computed tomography (SPECT) of the brain, newly reported in one study to be of use in evaluation of Lyme encephalopathy [13] . SPECT was not available when the study began, and only the last 7 patients entered into the study underwent SPECT imaging.
Treatment and follow-up according to protocol. The 18 patients who met entrance criteria for Lyme encephalopathy (the intentionto-treat group) were treated with iv ceftriaxone, 2 g once a day for 30 days. Treatment was administered at home. During therapy, complete blood cell count and liver function tests were monitored weekly. A follow-up visit was required 6 months after completion of therapy. At that visit, patients were asked to rate their symptoms as worse, unchanged, somewhat improved, greatly improved, or improved to normal compared with their pretreatment state. In addition, neuropsychological tests were repeated, and equivalent but different versions of the CVLT or SRT were used to minimize practice effects. If CSF abnormalities were present initially, the patients were requested to undergo repeated lumbar puncture for CSF analysis. Previous experience had shown that brain MRI did not change after antibiotic treatment [3] , and therefore, follow-up MRI was not done. However, after August 1992, posttreatment SPECT scanning was repeated in all patients. A final assessment was made 12-24 months after treatment either in the clinic or by telephone. Patients were again asked to assess their symptoms, but follow-up testing was not required.
Statistical analysis. For the CVLT, SRT, and Rey-Osterrieth Complex Figure Test , pre-and posttreatment data were compared, using a t test for related samples for the t scores (verbal learning) or by a repeated measures analysis of variance with age as a covariate (SRT and Complex figure). To compare the differences in pre-and posttreatment CSF protein and SPECT measurements, the two-tailed paired Student's t test was used.
Results
Patient characteristics. The 18 study patients were predominantly middle-aged men from endemic areas for Lyme disease in coastal New England. By definition, all had previous classical manifestations of Lyme disease, most commonly erythema migrans (72%) or oligoarticular arthritis (72%); only a minority (33%) had early, acute neuroborreliosis.
In the 13 patients whose disease onset was marked by erythema migrans, there were 3 subsequent periods of disease activity: (1) cardiac or early neurological involvement beginning a mean duration of 1 month after disease onset, (2) oligoarticular arthritis occurring after a mean duration of 8 months, and (3) late, chronic encephalopathy beginning after a mean duration of 6 years (table 1). It should be emphasized that oligoarticular arthritis was almost always quiescent at the onset of encephalopathy.
Prior to enrollment in our study, 15 (83%) of the 18 patients had been treated previously with antibiotics, usually oral regimens for early disease or Lyme arthritis. However, 4 patients (22%) had received iv antibiotics (table 1) . Of these 4, 1 patient had been treated for early Lyme neuroborreliosis with iv penicillin for 6 weeks. Three patients had been treated with iv ceftriaxone for р2 weeks, 1 for early neuroborreliosis, 1 for cardiac conduction block, and 1 as initial treatment for Lyme encephalopathy 3 years prior to study entry. Despite iv therapy, these 4 patients had progressive problems with memory; 3 had local production of antibody to B. burgdorferi in CSF, and 1 had a positive PCR test for borrelial DNA in CSF.
The most common symptom of Lyme encephalopathy was memory difficulty, usually requiring patients to compensate with new behaviors such as list making, relying on spouses, or making greater efforts to concentrate (table 2) . In all 18 patients, family members endorsed the problem with memory. Mild depression, irritability, headache, and somnolence were less common. Of the 18 patients, 5 had a coexistent, predominantly sensory polyneuropathy, manifested in 4 cases as distal paresthesia (e.g., "numbness," "pins and needles," or distal "jabbing"), usually in both the hands and feet, and in 1 case as thoracolumbar radicular pain (table 2). All 5 patients with neuropathy had sensory loss to vibration or pinprick in the feet. One patient had muscle weakness and areflexia. All 5 had documented abnormalities on electrophysiologic testing, as previously described [19] . Obvious memory loss on bedside testing was present in only 1 patient. However, on neuropsychological testing, 13 of the 18 patients had initial verbal memory scores that were below average (у1 SD), and 7 had below average (у1 SD) visual memory test scores (table 3). As in our previous studies [3, 12, 13] , all patients had an average to above average IQ, and none had significant abnormalities in any of the other neuropsychological domains of perception, language, or mood or in psychomotor skills. In particular, no patient met criteria for significant depression on the Beck Depression Inventory.
Of the 18 patients, 16 (87%) had an abnormal CSF analysis: 11 had a CSF/serum index of antibody to B. burgdorferi 11, 8 had an elevated total protein concentration, and 3 had a positive PCR test in CSF for B. burgdorferi DNA. Only 1 patient (7%) had a CSF pleocytosis (this patient had been previously treated with a 6-week course of iv penicillin). Fifteen patients (83%) were seropositive for B. burgdorferi by ELISA and IgG Western blotting, whereas 3 patients had only CSF abnormalities consistent with past or present B. burgdorferi infection. Brain MRI was usually normal, but 5 patients had multiple nonspecific white matter abnormalities in the central and peripheral white matter. In the 7 patients tested, quantitative SPECT showed multiple perfusion defects in the frontotemporal lobes, with a high perfusion defect index that was significantly greater than that in 28 normal subjects (mean index, 270 vs. 136, respectively; ) [13] . P ! .05 Treatment and follow-up. The 18 patients were treated with 2 g of iv ceftriaxone once a day for 30 days. About one-half of the patients experienced side effects of the medication, most commonly transient increases in liver transaminases or diarrhea (table 4) . No patient had to discontinue therapy.
Of the 18 patients, 15 completed the 6-month follow-up visit. Fourteen (93%) of the 15 patients reported gradual improvement in encephalopathic symptoms, usually beginning a few months after completion of therapy, and most said that they were now greatly improved (table 4). One patient was unchanged. Interviews with family members corroborated the improvement in memory noted by the patients. In the 15 patients, verbal learning, defined as the number of words learned over 5 trials, improved significantly from baseline values ( , t ϭ 3.52 ;
; figure 1A ). The 11 patients who were tested df ϭ 14 P ! .01 on different versions of the SRT showed improvement in both immediate ( , ; ) and delayed ( , F ϭ 6.16 df ϭ 1,9 P ! .04 F ϭ 5.55 ; ) memory after treatment. In the 11 patients df ϭ 1,9 P ! .05 in whom immediate and delayed visual memory were retested using a different version of the initial tests, results of both tests improved significantly ( ; figure 1B) . In contrast, there P ! .05 was no significant change in any of the other neuropsychological test results. In the 10 patients who consented to undergo repeated lumbar puncture, posttreatment spinal fluid protein levels were significantly less than pretreatment values ( , P ! .05 paired t test; figure 1C ). With each of these 3 parameters (verbal or visual memory or CSF protein), some patients had single values that were worse after treatment, but the other 2 parameters were improved. In all 7 patients who underwent quantitative SPECT, the perfusion defect index improved after treatment ( figure 1D ). The mean posttreatment perfusion index was significantly better than the pretreatment index (192 vs. 270, respectively;
). Antibody measurements in serum and P ! .01 CSF were not significantly changed after treatment.
Eight months after treatment, 1 patient reported a relapse. At the 6-month follow-up visit, he had noted improvement in memory, his neuropsychological tests of verbal memory had increased by 1 SD compared with pretreatment values, and his perfusion defect index had improved almost to the normal range. However, 2 months later, his encephalopathic symptoms returned, and his neuropsychological test results of verbal and visual memory deteriorated again. The CSF examination, which had been normal on study entry, was repeated and was again normal. Thus, although we lacked proof that his relapse resulted from treatment failure, he was retreated with a second 1-month course of iv ceftriaxone, 2 g per day, because of this possibility. He again experienced improvement in symptoms, which was sustained for the duration of the study. A final assessment was made of all 18 patients in the intention-to-treat group 12-24 months (average duration, 22 months) after treatment. In 12 patients, this was done in the clinic, and in 6, including the 3 patients who did not return for the 6-month follow-up assessment, it was done by telephone, All 18 patients, including the 1 patient who had relapsed, now reported that they were improved or even back to normal. Of the 15 patients who completed the study according to protocol, 5 said that they were now normal, 7 were greatly improved, and 3 were somewhat improved. Of the 3 patients in the intention-to-treat group who did not complete the study according to protocol, 2 rated themselves back to normal, and 1 was greatly improved.
Discussion
Months to years after the onset of Lyme disease, the 18 patients reported here developed subtle neuropsychiatric symptoms, primarily memory deficit, in most instances accompanied by abnormal results on neuropsychological tests of memory and CSF abnormalities of past or present B. burgdorferi infection. Following 1-month courses of iv ceftriaxone, all but 1 patient experienced gradual, sustained improvement in symptoms. Six months after treatment, the patients tested had significant improvement in verbal or visual memory tests and significantly lower CSF protein levels.
This study has several advantages compared with previous reports [3, 4, 6, 10, 11] : the entrance criteria required objective neuropsychological or CSF abnormalities, all patients received the same regimen of iv ceftriaxone for 4 weeks, objective outcome measurements were available in those who completed the study according to protocol, and 1-to 2-year follow-up information was available on all patients. However, the study also has the limitations of a small, uncontrolled case series. Ethical considerations about withholding antibiotic treatment from patients with objective neurological abnormalities as well as the rarity of the condition made it difficult to perform a case and control study of this entity. Because of the lack of a placebo control group, one may ask whether the improvement in our patients was due to placebo effect rather than antibiotic effect on spirochetal infection. But placebo effect, being a relatively short-lived phenomenon, is an unlikely explanation for the improved objective outcome measurements in our patients 6 months after therapy and for the sustained improvement in symptoms assessed over a 1-to 2-year period. Moreover, the fact that improvement was specifically in tests of memory and not in the other neuropsychiatric domains also speaks against a placebo effect. Improvement in memory test scores could have resulted from a learning effect, but different versions of the CVLT and SRT memory tests were employed for pre-and posttreatment tests. We do not think that the study was biased by the failure of 3 patients to complete the study according to protocol. Even though they did not have follow-up testing, they reported sustained improvement in their encephalopathic symptoms after therapy. Although no single test was performed in follow-up in all patients, all objective outcome measures in the study population improved significantly after therapy. Thus, we believe that any bias related to study design or implementation would not change the conclusion of the study, namely, that the patients experienced long-term objective improvement in neurocognitive function after ceftriaxone therapy.
Alternately, might the sustained improvement in patients have resulted from gradual resolution of previous acute neuroborreliosis and not from antibiotic therapy for active infection? CSF abnormalities in our patients were subtle or lacking altogether, and the most common abnormality, intrathecal antibody production to the spirochete, could be due to previous acute neuroborreliosis. However, only a minority of our patients had symptoms of acute neuroborreliosis, and most had long latent periods prior to the onset of chronic neurological symptoms, a finding reminiscent of neurosyphilis. In addition, borrelial DNA was detected in CSF by PCR in 3 of the current patients, providing the most direct evidence of B. burgdorferi in CSF. Furthermore, in a previous series of 8 patients with chronic neuroborreliosis who had positive PCR results prior to antibiotic therapy, all had negative results after successful treatment with ceftriaxone, as was the case here in the 1 patient who was retested after treatment [8] . In neurosyphilis as well, normal CSF analyses have been noted in some patients in whom Treponema pallidum has been cultured from CSF [20] . Finally, it has been hypothesized that active infection in extrathecal sites could result indirectly in central nervous system symptoms by diffusion intrathecally of neuroactive kynurenines [21] . However, by the time our patients had encephalopathic symptoms, they had a pure neurological picture without concurrent evidence of systemic disease, and the majority (72%) had laboratory evidence of past or present B. burgdorferi infection in spinal fluid. Thus, we believe that the sustained improvement in symptoms in our patients resulted from successful treatment of active infection of the brain with B. burgdorferi rather than from gradual resolution of previous infection.
Because of the rarity of Lyme encephalopathy, we did not randomize patients to receive ceftriaxone therapy for different durations. The only study of late Lyme disease in which this was done consisted primarily of patients with Lyme arthritis rather than those with chronic neuroborreliosis. It did not show a significant difference in outcome between those treated for 2 or 4 weeks [11] . In our previous series [3] , 6 (25%) of 24 patients relapsed 3-6 months after a 2-week course of iv ceftriaxone, compared with 1 (6%) of 18 patients in this series in whom relapse occurred 8 months after treatment. However, this dif-ference is not statistically significant ( ), and therefore we P ϭ .2 still lack proof that the relapse rate in patients with documented Lyme encephalopathy is lower with 30 days than with 14 days of therapy. On the other hand, our study strongly supports the current practice parameters for treatment of Lyme encephalopathy with relatively brief courses of iv ceftriaxone for 2-4 weeks [22] and not prolonged courses of antibiotics over many months.
In our experience, there is much confusion and disagreement about the diagnosis of Lyme encephalopathy. In particular, chronic fatigue syndrome, fibromyalgia, or somatoform disorders, which are much more common illnesses, may be mistaken for Lyme encephalopathy, neuropathy, or arthritis [23] [24] [25] . This problem is compounded by the fact that a small percentage of patients may develop these pain or fatigue syndromes in association with, or soon after, Lyme disease, in which case the entity may be called "post-Lyme disease syndrome" or "chronic Lyme disease" [25] . We believe that Lyme encephalopathy can usually be distinguished from these pain or fatigue syndromes. They are usually more disabling, and they are often associated with more generalized symptoms and more anxiety and depression [12] . Although these patients often report memory problems, their neuropsychological tests of memory and CSF results are usually normal [26] . Their affective symptoms, which are common in many chronic diseases, may predispose them to the perception of cognitive dysfunction. Patients with these syndromes may improve while being treated with antibiotic therapy, but they typically relapse within weeks to months after completion of therapy. This has led some physicians to continue antibiotic therapy for many months, and sometimes even years, with no evidence of sustained objective or subjective improvement in the patient's condition. Because these patients usually lack objective findings and because they do not experience sustained improvement with antibiotic therapy, we believe that post-Lyme disease syndrome is not caused by active infection with B. burgdorferi.
In contrast, all 18 patients in the present study had objective evidence of cognitive impairment, and most had evidence of past or present B. burgdorferi infection in CSF. Except for 1 patient who experienced 1 relapse, they had sustained improvement after treatment with 2 g of iv ceftriaxone once a day for 30 days. We conclude that Lyme encephalopathy can usually be treated successfully with a 1-month course of ceftriaxone, which suggests that it is caused by active infection with B. burgdorferi.
